Choice of first-line anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) based on the results of a systematic review and network meta-analysis
URBANSKA, E..
Choice of first-line anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) based on the results of a systematic review and network meta-analysis.
Precision Cancer Medicine, North America, 6,
may. 2023. Available at: <https://pcm.amegroups.org/article/view/7703>. Date accessed: 03 Nov. 2025.